COVID-19 treatments

Find out about approved and potential treatments for COVID-19 in Australia. Evidence-based guidelines help our health professionals provide the best care for people with COVID-19.

We closely track worldwide research into COVID-19 treatments.

The Therapeutic Goods Administration (TGA) assesses the safety and efficacy of COVID-19 treatments before provisionally approving their use in Australia.

Australian guidelines

The National COVID-19 Clinical Evidence Taskforce is a large group of clinical experts. It creates evidence-based Australian guidelines for the clinical care of people with COVID-19.

Healthcare workers in Australia treat patients with COVID-19 according to these guidelines.

The Clinical Evidence Taskforce continuously updates treatment recommendations using the best available evidence.

Treatments available from the NMS

The TGA has provisionally approved the following treatments for COVID-19. The National Medical Stockpile (NMS) distributes these treatments to state and territory governments for use in their health systems.

Regdanvimab (Regkirona)

The TGA provisionally approved Regkirona on 6 December 2021. It is used in adult patients who have confirmed SARS-CoV-2 infection.

Tocilizumab (Actemra)

The TGA provisionally approved Actemra on 1 December 2021. It is used in adult patients who are receiving systemic corticosteroids and require supplemental oxygen or mechanical ventilation.

Casirivimab and imdevimab (Ronapreve)

The TGA provisionally approved Ronapreve on 15 October 2021. It is used to treat patients aged 12 years and older with moderate to critical COVID-19. It is also used to prevent COVID-19 in patients aged 12 years and older who do not have antibodies to the coronavirus that causes COVID-19.

Sotrovimab (Xevudy)

The TGA provisionally approved Xevudy on 20 August 2021. It is used within the first 5 days of symptoms starting in patients aged 12 years or older with mild to moderate COVID-19.

Remdesivir (Veklury)

The TGA provisionally approved Veklury on 10 July 2020. It is used in adults hospitalised with moderate to severe COVID-19.

Treatments under evaluation

The TGA is also currently evaluating:

  • molnupiravir, an antiviral treatment that comes in tablet form

  • a treatment called PF-07321332, which will be used in combination with ritonavir

  • tixagevimab and cilgavimab (Evusheld), a treatment consisting of two monoclonal antibodies.

The Australian Government has ordered supplies of molnupiravir and PF-07321332. They will be available for use in Australia if the TGA grants approval.

Off-label use of medication

TGA approval for a medicine to treat one condition, does not mean that it is safe to treat another condition. Doctors who prescribe medicines 'off-label' must consider the risks for the patient. Patients must provide informed consent.

Not recommended for COVID-19

The TGA has not approved, and the National COVID-19 Clinical Evidence Taskforce guidelines do not recommend, the following treatments for COVID-19.

Ivermectin, doxycycline, zinc

There is not enough evidence to support the safe and effective use of these drugs (separately, or in combination) to prevent or treat COVID-19.

The Clinical Evidence Taskforce does not recommend the use of ivermectin, doxycycline or zinc outside of properly conducted clinical trials with appropriate ethical approval.

Hydroxychloroquine

The Clinical Evidence Taskforce strongly recommends that people do not use hydroxychloroquine to treat COVID-19.

Hydroxychloroquine has well known risks including:

  • toxic effects on the heart (potentially leading to heart attacks)

  • irreversible eye damage

  • lowering blood sugar levels (potentially leading to coma).

Last updated: 
23 December 2021

Help us improve health.gov.au

If you would like a response please use the enquiries form instead.